Last reviewed · How we verify
Natto extract (Nattokinase)
Nattokinase is a serine protease enzyme that directly degrades fibrin clots and enhances fibrinolysis to promote thrombus dissolution.
Nattokinase is a serine protease enzyme that directly degrades fibrin clots and enhances fibrinolysis to improve blood flow. Used for Thrombosis prevention and management, Cardiovascular health and blood flow improvement, Post-thrombotic syndrome.
At a glance
| Generic name | Natto extract (Nattokinase) |
|---|---|
| Sponsor | Changhua Christian Hospital |
| Drug class | Fibrinolytic enzyme |
| Target | Fibrin |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Nattokinase, derived from fermented soybeans (natto), is a fibrinolytic enzyme that breaks down fibrin, the primary structural component of blood clots. It works through direct fibrinolysis and may also enhance the body's endogenous fibrinolytic system by increasing plasmin activity. This mechanism is proposed to improve blood flow and reduce thrombotic risk.
Approved indications
- Thrombotic disorders and cardiovascular disease prevention
- Blood clot dissolution and fibrinolysis support
Common side effects
- Bleeding or increased bleeding risk
- Gastrointestinal upset
- Allergic reactions
Key clinical trials
- Efficacy and Safety of Natto Extract (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Natto extract (Nattokinase) CI brief — competitive landscape report
- Natto extract (Nattokinase) updates RSS · CI watch RSS
- Changhua Christian Hospital portfolio CI